<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00660985</url>
  </required_header>
  <id_info>
    <org_study_id>RD.06.SPR.18115</org_study_id>
    <nct_id>NCT00660985</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%</brief_title>
  <official_title>A Pharmacokinetic Study to Compare the Systemic Exposure to Adapalene During Dermal Application of Either Differin® Gel, 0.3% (Adapalene 0.3%) or Differin® Gel, 0.1% (Adapalene 0.1%) for 30 Days in Subjects With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <brief_summary>
    <textblock>
      Phase 4 commitment pharmacokinetic study to determine systemic exposure to adapalene.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, double-blind, randomized, parallel group study enrolling male or female
      subjects with acne vulgaris.

      Screening will take place within 14 days prior to Baseline. At the Baseline visit, and at
      each study day up to Day 30, a trained nurse or technician will apply 2 grams of study
      medication (either Differin® Gel, 0.3% or Differin® Gel, 0.1%) to the face, upper part of
      chest, and upper part of back of the subjects. To ensure maximal usage conditions, 2 grams
      study medication will be applied once daily to a total body surface area of approximately
      1000 cm², which is equivalent to 2 mg/cm2.

      Subjects will arrive at the clinic the night before on visit days (Day 1, Day 15 and Day 30)
      when PK blood samples will be drawn. Subjects will be discharged from the clinic on Day 2 and
      Day 16 following the 24-hour post-dose blood sample, and on Day 31 after the 36-hour
      post-dose blood samples.

      Cutaneous safety (local tolerability assessments) will be assessed, by recording erythema,
      scaling, dryness, and stinging/burning sensation as separate scores on the face, upper part
      of the chest, and upper part of the back using a 4-point scale (0 = None to 3 = Severe).
      Local tolerability assessments will be performed weekly on Day 1, 8, 15, 22 and Day 30, prior
      application of study medication.

      Efficacy will be evaluated by Inflammatory and Non-inflammatory lesion counts on the face
      performed at Screening, Baseline (Day 1), and on Day 30.

      Subjects will have routine laboratory tests (fasting hematology, blood chemistry) performed
      at Screening and at Day 30 visits.

      Blood samples for determination of adapalene plasma concentrations will be drawn on Day 1,
      Day 15, and Day 30 before the morning study medication application (pre-dose) and 1, 2, 4, 6,
      8, 10, 12, 16 and 24 hours after application of study medication; and additionally after the
      last study medication application (Day 31, 32, 33) at 32, 36, 48 and 72 hours post-dose.

      The adapalene plasma concentrations will be determined by a high performance liquid
      chromatography (HPLC) and fluorescence detection method.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (ng/mL) at Day 1</measure>
    <time_frame>T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr (post dose)</time_frame>
    <description>the observed peak drug (adapalene) concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (ng/mL) at Day 15</measure>
    <time_frame>T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr (post dose)</time_frame>
    <description>the observed peak drug (adapalene) concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (ng/mL) at Day 30</measure>
    <time_frame>T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr, T32hr, T36hr, T48hr, T 72hr (post dose)</time_frame>
    <description>the observed peak drug (adapalene) concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax (hr) at Day 1</measure>
    <time_frame>T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr (post dose)</time_frame>
    <description>the time at which Cmax occurs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax (hr) at Day 15</measure>
    <time_frame>T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr (post dose)</time_frame>
    <description>the time at which Cmax occurs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax (hr) at Day 30</measure>
    <time_frame>T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr, T32hr, T36hr, T48hr, T72hr (post dose)</time_frame>
    <description>the time at which Cmax occurs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve for 0 to 24 Hours Post Dose Measured on Day 1 (AUC (0-24))</measure>
    <time_frame>T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr (post dose)</time_frame>
    <description>area under the concentration-time curve calculated mixed linear-logarithmic trapezoidal method from pre-application (T0) through 24 hr (corresponding to the dosing interval)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve for 0 to 24 Hours Post Dose Measured on Day 15 (AUC (0-24))</measure>
    <time_frame>T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr (post dose)</time_frame>
    <description>area under the concentration-time curve calculated mixed linear-logarithmic trapezoidal method from pre-application (T0) through 24hr (corresponding to the dosing interval)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve for 0 to 24 Hours Post Dose Measured on Day 30 (AUC (0-24))</measure>
    <time_frame>T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr, T32hr, T36hr, T48hr, T72hr (post dose)</time_frame>
    <description>area under the concentration-time curve calculated mixed linear-logarithmic trapezoidal method from pre-application (T0) through 24hr (corresponding to the dosing interval)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Differin® Gel, 0.3%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gel, 0.3%, 2g, once daily for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Differin® Gel, 0.1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gel, 0.1%, 2g, once daily for 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene</intervention_name>
    <description>Gel, 0.3%, 2g, once daily for 30 days</description>
    <arm_group_label>Differin® Gel, 0.3%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene</intervention_name>
    <description>Gel, 0.1%, 2g, once daily for 30 days</description>
    <arm_group_label>Differin® Gel, 0.1%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18 to 35 years of age

          -  Clinical diagnosis of acne vulgaris

          -  Minimum of 20 Inflammatory

          -  Minimum of 20 Non-inflammatory lesions

          -  The subject has a body weight between 45 and 100 kg, and a Body Mass Index (BMI)
             between 18 and 30Kg/m2

        Exclusion Criteria:

          -  More than 1 nodule or any cyst on the face (excluding the nose)

          -  Acne conglobata, acne fulminans, secondary acne or severe acne

          -  Underlying diseases or other dermatological conditions that require the use of
             interfering topical or systemic therapy

          -  Pregnant or nursing or planning a pregnancy

          -  Surgical or medical condition which might interfere with the absorption, distribution,
             metabolism, or excretion of the drug

          -  Known allergies to any of the ingredients of the study medication

          -  History of alcohol or drug abuse or positive test results for any drug abuse

          -  Positive test results for hepatitis B surface antigen (HBs-Ag), hepatitis C virus
             (HCV) or human immunodeficiency virus antibodies (HIV Ab)

          -  Use of prohibited medications prior to the study unless appropriate washout period is
             documented
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Graeber, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galderma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DermResearch, Inc.</name>
      <address>
        <city>Austin,</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J&amp;S Studies, Inc.</name>
      <address>
        <city>College Station,</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2008</study_first_submitted>
  <study_first_submitted_qc>April 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2008</study_first_posted>
  <results_first_submitted>October 15, 2009</results_first_submitted>
  <results_first_submitted_qc>November 23, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 29, 2009</results_first_posted>
  <last_update_submitted>January 19, 2011</last_update_submitted>
  <last_update_submitted_qc>January 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Michael Graeber, MD, Head of US Development:</name_title>
    <organization>Galderma R&amp;D</organization>
  </responsible_party>
  <keyword>Acne vulgaris</keyword>
  <keyword>Differin</keyword>
  <keyword>Adapalene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adapalene</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Differin® Gel, 0.3%</title>
          <description>Gel, 0.3%, 2g, once daily for 30 days</description>
        </group>
        <group group_id="P2">
          <title>Differin® Gel, 0.1%</title>
          <description>Gel, 0.1%, 2g, once daily for 30 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Differin® Gel, 0.3%</title>
          <description>Gel, 0.3%, 2g, once daily for 30 days</description>
        </group>
        <group group_id="B2">
          <title>Differin® Gel, 0.1%</title>
          <description>Gel, 0.1%, 2g, once daily for 30 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.4" spread="4.87"/>
                    <measurement group_id="B2" value="21.3" spread="3.78"/>
                    <measurement group_id="B3" value="22.4" spread="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax (ng/mL) at Day 1</title>
        <description>the observed peak drug (adapalene) concentration</description>
        <time_frame>T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr (post dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Differin® Gel, 0.3%</title>
            <description>Gel, 0.3%, 2g, once daily for 30 days</description>
          </group>
          <group group_id="O2">
            <title>Differin® Gel, 0.1%</title>
            <description>Gel, 0.1%, 2g, once daily for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (ng/mL) at Day 1</title>
          <description>the observed peak drug (adapalene) concentration</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.10"/>
                    <measurement group_id="O2" value="0.02" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax (ng/mL) at Day 15</title>
        <description>the observed peak drug (adapalene) concentration</description>
        <time_frame>T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr (post dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Differin® Gel, 0.3%</title>
            <description>Gel, 0.3%, 2g, once daily for 30 days</description>
          </group>
          <group group_id="O2">
            <title>Differin® Gel, 0.1%</title>
            <description>Gel, 0.1%, 2g, once daily for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (ng/mL) at Day 15</title>
          <description>the observed peak drug (adapalene) concentration</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.09"/>
                    <measurement group_id="O2" value="0.04" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax (ng/mL) at Day 30</title>
        <description>the observed peak drug (adapalene) concentration</description>
        <time_frame>T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr, T32hr, T36hr, T48hr, T 72hr (post dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Differin® Gel, 0.3%</title>
            <description>Gel, 0.3%, 2g, once daily for 30 days</description>
          </group>
          <group group_id="O2">
            <title>Differin® Gel, 0.1%</title>
            <description>Gel, 0.1%, 2g, once daily for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (ng/mL) at Day 30</title>
          <description>the observed peak drug (adapalene) concentration</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.10"/>
                    <measurement group_id="O2" value="0.03" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax (hr) at Day 1</title>
        <description>the time at which Cmax occurs</description>
        <time_frame>T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr (post dose)</time_frame>
        <population>26 subjects in the Differin Gel 0.3% and 25 subjects in the Differin Gel 0.1% were included in the study. 14 subjects in the Differin Gel 0.3% and 4 subjects in the Differin Gel 0.1% were detectable at Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Differin® Gel, 0.3%</title>
            <description>Gel, 0.3%, 2g, once daily for 30 days</description>
          </group>
          <group group_id="O2">
            <title>Differin® Gel, 0.1%</title>
            <description>Gel, 0.1%, 2g, once daily for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (hr) at Day 1</title>
          <description>the time at which Cmax occurs</description>
          <population>26 subjects in the Differin Gel 0.3% and 25 subjects in the Differin Gel 0.1% were included in the study. 14 subjects in the Differin Gel 0.3% and 4 subjects in the Differin Gel 0.1% were detectable at Day 1.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="6"/>
                    <measurement group_id="O2" value="11" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax (hr) at Day 15</title>
        <description>the time at which Cmax occurs</description>
        <time_frame>T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr (post dose)</time_frame>
        <population>26 subjects in the Differin Gel 0.3% and 25 subjects in the Differin Gel 0.1% were included in the study. 23 subjects in the Differin Gel 0.3% and 7 subjects in the Differin Gel 0.1% were detectable at Day 15.</population>
        <group_list>
          <group group_id="O1">
            <title>Differin® Gel, 0.3%</title>
            <description>Gel, 0.3%, 2g, once daily for 30 days</description>
          </group>
          <group group_id="O2">
            <title>Differin® Gel, 0.1%</title>
            <description>Gel, 0.1%, 2g, once daily for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (hr) at Day 15</title>
          <description>the time at which Cmax occurs</description>
          <population>26 subjects in the Differin Gel 0.3% and 25 subjects in the Differin Gel 0.1% were included in the study. 23 subjects in the Differin Gel 0.3% and 7 subjects in the Differin Gel 0.1% were detectable at Day 15.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" spread="8"/>
                    <measurement group_id="O2" value="11" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax (hr) at Day 30</title>
        <description>the time at which Cmax occurs</description>
        <time_frame>T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr, T32hr, T36hr, T48hr, T72hr (post dose)</time_frame>
        <population>26 subjects in the Differin Gel 0.3% and 25 subjects in the Differin Gel 0.1% were included in the study. 20 subjects in the Differin Gel 0.3% and 4 subjects in the Differin Gel 0.1% were detectable at Day 30.</population>
        <group_list>
          <group group_id="O1">
            <title>Differin® Gel, 0.3%</title>
            <description>Gel, 0.3%, 2g, once daily for 30 days</description>
          </group>
          <group group_id="O2">
            <title>Differin® Gel, 0.1%</title>
            <description>Gel, 0.1%, 2g, once daily for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (hr) at Day 30</title>
          <description>the time at which Cmax occurs</description>
          <population>26 subjects in the Differin Gel 0.3% and 25 subjects in the Differin Gel 0.1% were included in the study. 20 subjects in the Differin Gel 0.3% and 4 subjects in the Differin Gel 0.1% were detectable at Day 30.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" spread="6"/>
                    <measurement group_id="O2" value="12" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve for 0 to 24 Hours Post Dose Measured on Day 1 (AUC (0-24))</title>
        <description>area under the concentration-time curve calculated mixed linear-logarithmic trapezoidal method from pre-application (T0) through 24 hr (corresponding to the dosing interval)</description>
        <time_frame>T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr (post dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Differin® Gel, 0.3%</title>
            <description>Gel, 0.3%, 2g, once daily for 30 days</description>
          </group>
          <group group_id="O2">
            <title>Differin® Gel, 0.1%</title>
            <description>Gel, 0.1%, 2g, once daily for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve for 0 to 24 Hours Post Dose Measured on Day 1 (AUC (0-24))</title>
          <description>area under the concentration-time curve calculated mixed linear-logarithmic trapezoidal method from pre-application (T0) through 24 hr (corresponding to the dosing interval)</description>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="1.58"/>
                    <measurement group_id="O2" value="0.31" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve for 0 to 24 Hours Post Dose Measured on Day 15 (AUC (0-24))</title>
        <description>area under the concentration-time curve calculated mixed linear-logarithmic trapezoidal method from pre-application (T0) through 24hr (corresponding to the dosing interval)</description>
        <time_frame>T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr (post dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Differin® Gel, 0.3%</title>
            <description>Gel, 0.3%, 2g, once daily for 30 days</description>
          </group>
          <group group_id="O2">
            <title>Differin® Gel, 0.1%</title>
            <description>Gel, 0.1%, 2g, once daily for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve for 0 to 24 Hours Post Dose Measured on Day 15 (AUC (0-24))</title>
          <description>area under the concentration-time curve calculated mixed linear-logarithmic trapezoidal method from pre-application (T0) through 24hr (corresponding to the dosing interval)</description>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" spread="1.75"/>
                    <measurement group_id="O2" value="0.50" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve for 0 to 24 Hours Post Dose Measured on Day 30 (AUC (0-24))</title>
        <description>area under the concentration-time curve calculated mixed linear-logarithmic trapezoidal method from pre-application (T0) through 24hr (corresponding to the dosing interval)</description>
        <time_frame>T0 (predose), T1hour (hr), T2hr, T4hr, T6 hr, T8 hr, T10hr, T12hr, T16hr, T24hr, T32hr, T36hr, T48hr, T72hr (post dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Differin® Gel, 0.3%</title>
            <description>Gel, 0.3%, 2g, once daily for 30 days</description>
          </group>
          <group group_id="O2">
            <title>Differin® Gel, 0.1%</title>
            <description>Gel, 0.1%, 2g, once daily for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve for 0 to 24 Hours Post Dose Measured on Day 30 (AUC (0-24))</title>
          <description>area under the concentration-time curve calculated mixed linear-logarithmic trapezoidal method from pre-application (T0) through 24hr (corresponding to the dosing interval)</description>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.64" spread="1.66"/>
                    <measurement group_id="O2" value="0.42" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Differin® Gel, 0.3%</title>
          <description>Gel, 0.3%, 2g, once daily for 30 days</description>
        </group>
        <group group_id="E2">
          <title>Differin® Gel, 0.1%</title>
          <description>Gel, 0.1%, 2g, once daily for 30 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Graeber, MD, Head of Global Clinical Project Management and US Development</name_or_title>
      <organization>Galderma</organization>
      <phone>609-860-8201</phone>
      <email>michael.graeber@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

